BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham EL, Koralnik IJ, Liotta EM. Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics 2022. [PMID: 35861926 DOI: 10.1007/s13311-022-01267-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Stamm B, Royan R, Trifan G, Alvarado-Dyer R, Velez FGS, Taylor W, Pinna P, Reish NJ, Vargas A, Goldenberg FD, Schneck MJ, Biller J, Testai F, Caprio FZ, Chou SH, Gorelick PB, Liotta EM, Batra A. Household income is associated with functional outcomes in a multi-institutional cohort of patients with ischemic stroke and COVID-19. J Stroke Cerebrovasc Dis 2023;32:107059. [PMID: 36842351 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107059] [Reference Citation Analysis]
2 Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, Pardo CA, Choi A, Cho SM. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells 2023;12. [PMID: 36899952 DOI: 10.3390/cells12050816] [Reference Citation Analysis]
3 Rothstein TL. Cortical Grey matter volume depletion links to neurological sequelae in post COVID-19 "long haulers". BMC Neurol 2023;23:22. [PMID: 36647063 DOI: 10.1186/s12883-023-03049-1] [Reference Citation Analysis]
4 Casabianca M, Caula C, Titomanlio L, Lenglart L. Neurological consequences of SARS-CoV-2 infections in the pediatric population. Front Pediatr 2023;11:1123348. [PMID: 36865695 DOI: 10.3389/fped.2023.1123348] [Reference Citation Analysis]
5 Santi Laurini G, Montanaro N, Motola D. Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. J Clin Med 2022;12. [PMID: 36614834 DOI: 10.3390/jcm12010034] [Reference Citation Analysis]
6 Ibrahim A, Humphries UW, Khan A, Iliyasu Bala S, Baba IA, Rihan FA. COVID-19 Model with High- and Low-Risk Susceptible Population Incorporating the Effect of Vaccines. Vaccines (Basel) 2022;11. [PMID: 36679848 DOI: 10.3390/vaccines11010003] [Reference Citation Analysis]
7 Calabrese C, Kirchner E, Calabrese LH. Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications. Best Practice & Research Clinical Rheumatology 2022. [DOI: 10.1016/j.berh.2022.101794] [Reference Citation Analysis]
8 Dang TQ, La DT, Tran TN. Myeloencephalitis as the only presentation of Omicron SARS-CoV-2 infection. BMJ Case Rep 2022;15:e251922. [DOI: 10.1136/bcr-2022-251922] [Reference Citation Analysis]
9 Xu Z, Zou Y, Gao X, Niu M, Li J, Xue L, Jiang S. Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. Front Pharmacol 2022;13:1041331. [DOI: 10.3389/fphar.2022.1041331] [Reference Citation Analysis]
10 Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1003103] [Reference Citation Analysis]